CriticalSSRI (selective serotonin reuptake inhibitor)×First-generation antihistamine with anxiolytic activity
Updated · Methodology
Mechanism
Citalopram prolongs the QT interval. Post-marketing reports describe QT prolongation and ventricular arrhythmias, including torsade de pointes (citalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label describes the QT effect as dose-dependent (citalopram label, US Food and Drug Administration, FDA). Hydroxyzine is also associated with QT prolongation. Post-marketing cases of QT prolongation and torsade de pointes with hydroxyzine occurred mostly in people with other risk factors, electrolyte disturbances or concomitant medicines (hydroxyzine SmPC, AEMPS). The pair has not been studied. Still, the citalopram SmPC does not rule out an additive effect on the QT interval. The hydroxyzine SmPC explicitly states that combining it with citalopram raises the risk of arrhythmia (AEMPS). A relevant effect on citalopram metabolism is unlikely. Hydroxyzine inhibits CYP2D6, but three enzymes break down citalopram (CYP2C19, CYP3A4 and CYP2D6), and the other two can offset inhibition of one (hydroxyzine and citalopram SmPCs, AEMPS).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Ventricular arrhythmias, including torsade de pointes, cause dizziness, palpitations and fainting and can end in sudden death (citalopram label, US Food and Drug Administration, FDA). After citalopram was marketed, such arrhythmias occurred mostly in women and in people with low potassium, a pre-existing long QT interval or heart disease (citalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Hydroxyzine itself causes drowsiness, headache, fatigue and dry mouth (hydroxyzine SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish hydroxyzine summary of product characteristics (SmPC) contraindicates hydroxyzine with drugs that prolong the QT interval or cause torsade de pointes and names citalopram (hydroxyzine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish citalopram SmPC also contraindicates citalopram with QT-prolonging drugs (citalopram SmPC, AEMPS), and the US citalopram label says to avoid such combinations (citalopram label, US Food and Drug Administration, FDA). The US hydroxyzine label only advises caution with QT-prolonging drugs, citalopram included (hydroxyzine label, FDA); the Spanish SmPCs are stricter. Hydroxyzine is also contraindicated in known QT prolongation, cardiovascular disease, low potassium or magnesium, a family history of sudden cardiac death and significant bradycardia (hydroxyzine SmPC, AEMPS). Citalopram is contraindicated in a history of long QT or congenital long QT syndrome (citalopram SmPC, AEMPS). Correct low potassium and magnesium before starting citalopram (citalopram SmPC, AEMPS), and stop citalopram if QTc stays above 500 ms (citalopram label, FDA). If hydroxyzine and citalopram have nevertheless been taken together and signs of arrhythmia appear, stop hydroxyzine (hydroxyzine SmPC, AEMPS), and stop citalopram and record an electrocardiogram (citalopram SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Citalopram, Seropram 30 mg (nº registro 63564) (2024)– AEMPS, CIMA, nº registro 63564 (Seropram 30 mg comprimidos recubiertos con película, Lundbeck), revisión 01/2024, secciones 4.2, 4.3, 4.4, 4.5 y 5.1
- FDA: Celexa (citalopram) – Prescribing Information (2023)– FDA, DailyMed SPL, Allergan, setid 4259d9b1-de34-43a4-85a8-41dd214e9177, version 40, revised 10/2023, sections 4, 5.2, 5.3, 5.4, 7, 12.3 and 17
- AEMPS: Ficha técnica: Hidroxizina (nº registro 26308), sección 4.5 (2023)– AEMPS, CIMA, nº registro 26308 (Atarax 25 mg comprimidos recubiertos con película, UCB Pharma), revisión 02/2023, secciones 4.3, 4.4, 4.5 y 4.8
- FDA: Hydroxyzine Hydrochloride Tablets, USP (hydroxyzine) prescribing information (2026)– FDA, DailyMed setid 9de2de56-614f-4294-8794-d30758cf5f70 (Aurobindo Pharma), revisión 03/2026 (versión 2), Contraindications, Precautions (QT Prolongation/Torsade de Pointes), Overdosage